A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis (DR-TB) and provide access to effective cure and prevention of DR-TB throughout the world.

Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.

Sign up for our monthly newsletter and review of recent literature!

To view our most recent newsletter click here!

 


Developments in MDR-TB


Advocates raise serious concerns about errors in the WHO guidelines for the treatment of drug-resistant TB

On 23 April 2019, TB advocates sent an open letter to Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), expressing their serious concerns about the WHO Global TB Program’s ability to issue evidence-based guidelines for the treatment of drug-resistant TB.
Read the full article here.